MedTrace Logo

MAnnitol for Blood Pressure Stability in HemoDialysis (MAP-HD)

NCT04428372 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2025-11-24

No results posted yet for this study

Summary

This proposal will measure the effects of mannitol administration versus placebo in hypotensive-prone, adult, maintenance hemodialysis patients with respect to changes in patient symptoms and blood pressure stability.

Conditions

  • Hemodialysis Complication
  • Hemodynamic Instability

Interventions

DRUG

Mannitol

Hypertonic mannitol infusion

DRUG

0.9% saline

Normal saline 'placebo' arm

Sponsors & Collaborators

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Finnian R Mc Causland, MBBCH, MMSc · Brigham and Women's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-06
Primary Completion
2024-12-31
Completion
2024-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04428372 on ClinicalTrials.gov